πŸ“£ VC round data is live. Check it out!

Abeona Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Abeona Therapeutics and similar public comparables like Surrozen, Replimune Group, Neumora Therapeutics, Bicycle Therapeutics and more.

Abeona Therapeutics Overview

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.


Founded

1974

HQ

United States

Employees

136

Financials (LTM)

Revenue: $26M
Net Income: $30M

EV

$170M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Abeona Therapeutics Financials

Abeona Therapeutics reported last 12-month revenue of $26M.

In the same LTM period, Abeona Therapeutics generated $21M in gross profit and $30M in net income.

Revenue (LTM)


Abeona Therapeutics P&L

In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of $79M.

Abeona Therapeutics is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.

See analyst estimates for Abeona Therapeutics
LTMLast FY202320242025202620272028
Revenue$26M$6M$4Mβ€”$6M
Gross Profit$21M$2M$2Mβ€”$2M
Gross Margin79%41%54%β€”41%
EBITDAβ€”$79M($51M)($57M)$79M
EBITDA Marginβ€”1350%(1445%)β€”1350%
EBIT Margin(288%)(1537%)(1377%)β€”(1537%)
Net Profit$30M$71M($54M)($64M)$71M
Net Margin113%1223%(1548%)β€”1223%

Financial data powered by Morningstar, Inc.

Abeona Therapeutics Stock Performance

Abeona Therapeutics has current market cap of $336M, and enterprise value of $170M.

Market Cap Evolution


Abeona Therapeutics' stock price is $5.91.

Abeona Therapeutics share price increased by 8.5% in the last 30 days, and decreased by 5.3% in the last year.

Abeona Therapeutics has an EPS (earnings per share) of $1.25.

See more trading valuation data for Abeona Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$170M$336M2.3%8.5%15.4%-5.3%$1.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Abeona Therapeutics Valuation Multiples

Abeona Therapeutics trades at 6.4x EV/Revenue multiple, and 2.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Abeona Therapeutics

EV / Revenue (LTM)


Abeona Therapeutics Financial Valuation Multiples

As of May 9, 2026, Abeona Therapeutics has market cap of $336M and EV of $170M.

Abeona Therapeutics has a P/E ratio of 11.3x.

LTMLast FY202320242025202620272028
EV/Revenue6.4x29.1x48.5xβ€”29.1x
EV/EBITDAβ€”2.2x(3.4x)(3.0x)2.2x
EV/EBIT(2.2x)(1.9x)(3.5x)(2.6x)(1.9x)
EV/Gross Profit8.2x70.8x89.5xβ€”70.8x
P/E11.3x4.7x(6.2x)(5.3x)4.7x
EV/FCFβ€”(2.0x)(4.5x)(2.9x)(2.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Abeona Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Abeona Therapeutics Margins & Growth Rates

Abeona Therapeutics grew revenue by 1002% but net profit decreased by 164% in the last fiscal year.

In the most recent fiscal year, Abeona Therapeutics reported gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.

See estimated margins and future growth rates for Abeona Therapeutics

Abeona Therapeutics Margins

Last FY20252026202720282029
Gross Margin41%41%79%
EBITDA Margin1350%1350%β€”
EBIT Margin(1537%)(1537%)(79%)
Net Margin1223%1223%(71%)
FCF Margin(1448%)(1448%)β€”

Abeona Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth1002%(100%)β€”1002%
Gross Profit Growth2024%(100%)β€”2024%
EBITDA Growthβ€”12%(239%)β€”
EBIT Growth(43%)33%39%(43%)
Net Profit Growth(164%)18%(212%)(164%)
FCF Growthβ€”57%44%β€”

Data powered by FactSet, Inc. and Morningstar, Inc.

Abeona Therapeutics Operational KPIs

Abeona Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Access forward-looking KPIs for Abeona Therapeutics
LTMLast FY20232025202620272028
Revenue per Employeeβ€”$0.0Mβ€”β€”
Opex per Employeeβ€”$0.7Mβ€”β€”
G&A Expenses to Revenue264%1117%543%1117%
R&D Expenses to Revenue97%461%888%461%
Opex to Revenueβ€”1578%1431%1578%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Abeona Therapeutics Competitors

Abeona Therapeutics competitors include Surrozen, Replimune Group, Neumora Therapeutics, Bicycle Therapeutics, Lavipharm, Immuneering, Cuorips, Tanvex BioPharma, DiaMedica and Lineage Cell Therapeutics.

Most Abeona Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Surrozen67.8x52.3x(5.7x)β€”
Replimune Groupβ€”124.8x(0.6x)(0.7x)
Neumora Therapeuticsβ€”β€”(1.0x)(1.2x)
Bicycle Therapeutics(2.9x)(3.8x)1.0x1.0x
Lavipharm5.0xβ€”21.5xβ€”
Immuneeringβ€”β€”(2.9x)β€”
Cuorips256.6xβ€”(94.0x)β€”
Tanvex BioPharma27.7xβ€”(10.2x)β€”

This data is available for Pro users. Sign up to see all Abeona Therapeutics competitors and their valuation data.

Start Free Trial

Abeona Therapeutics Funding History

Before going public, Abeona Therapeutics raised $4M in total equity funding, across 2 rounds.


Abeona Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-14Seedβ€”$4Mβ€”β€”
Dec-13Seedβ€”$800Kβ€”β€”

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Abeona Therapeutics

When was Abeona Therapeutics founded?Abeona Therapeutics was founded in 1974.
Where is Abeona Therapeutics headquartered?Abeona Therapeutics is headquartered in United States.
How many employees does Abeona Therapeutics have?As of today, Abeona Therapeutics has over 136 employees.
Who is the CEO of Abeona Therapeutics?Abeona Therapeutics' CEO is Vishwas Seshadri.
Is Abeona Therapeutics publicly listed?Yes, Abeona Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Abeona Therapeutics?Abeona Therapeutics trades under ABEO ticker.
When did Abeona Therapeutics go public?Abeona Therapeutics went public in 1980.
Who are competitors of Abeona Therapeutics?Abeona Therapeutics main competitors include Surrozen, Replimune Group, Neumora Therapeutics, Bicycle Therapeutics, Lavipharm, Immuneering, Cuorips, Tanvex BioPharma, DiaMedica, Lineage Cell Therapeutics.
What is the current market cap of Abeona Therapeutics?Abeona Therapeutics' current market cap is $336M.
What is the current revenue of Abeona Therapeutics?Abeona Therapeutics' last 12 months revenue is $26M.
What is the current revenue growth of Abeona Therapeutics?Abeona Therapeutics revenue growth (NTM/LTM) is 256%.
What is the current EV/Revenue multiple of Abeona Therapeutics?Current revenue multiple of Abeona Therapeutics is 6.4x.
Is Abeona Therapeutics profitable?Yes, Abeona Therapeutics is net-income-positive (as of the last 12 months).
What is the current net income of Abeona Therapeutics?Abeona Therapeutics' last 12 months net income is $30M.
How many companies Abeona Therapeutics has acquired to date?Abeona Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Abeona Therapeutics has invested to date?Abeona Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Abeona Therapeutics

Lists including Abeona Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial